ijddr

International Journal of Drug Development and Research

ISSN - 0975-9344

- (2013) Volume 5, Issue 3

View PDF Download PDF

The in Vitro effect of clarithromycin on amastigote of Leishmania donovani

 

Author info »

Abstract

Backgrounds and objectives: Leishmania donovani is one of the most common species responsible for visceral leishmaniasis (VL) in India, Bangladesh and Sudan. The pentavalent antimonials are widely used as intramuscular route in the treatment of VL, but increase in resistance to this agent led to investigation of new drugs. We undertook this study to identify an alternative to current leishmaniasis treatment. Methods: The in vitro activities of clarithromycin, amphotericin B, sodium stibogluconate and paromomycin were evaluated against drug- sensitive visceral Leishmania (amastigote) strain. A standard two fold serial dilution method in a 24- well plate was used to determine the 50% inhibitory concentration (IC50) against intracellular amastigotes in mouse peritoneal macrophages. Results: We determined the susceptibilities of both extracellular and intracellular drug sensitive amastigotes to clarithromycin and compared with amphotericin B, sodium stibogluconate and paromomycin. IC50 values of clarithromycin were found to be 87μM and 51μM for extracellular and intracellular amastigotes, respectively. 50% cytotoxic concentration (CC50) of clarithromycin in mouse peritoneal macrophage was found to be 1596μM. Selectivity indexes in cellular model for both clarithromycin and paromomycin were found to be 31, whereas selectivity index for sodium stibogluconate was found to be 17. Interpretation and conclusion: Our data suggested that clarithromycin was effective on L. donovani amastigotes in extracellular and cellular models. Clarithromycin was found to be equipotent to paromomycin when selectivity index was considered. Moreover, clarithromycin was more potent than sodium stibogluconate. Activity of clarithromycin against L. donovani may offer an alternative to current leishmaniasis treatment

References

  1. Cavalli A, Bolognesi ML. Neglected tropicaldiseases: multitarget-directed ligands in thesearch for novel lead candidates againstTrypanosomaand Leishmania. J Med Chem2009; 52: 7339-7359.
  2. Berman JD. Chemotherapy of leishmaniasis:biochemical mechanism, clinical efficacy, andfuture strategies. Rev Infect Dis 1988; 10: 562-586.
  3. Araujo FG, Shepard RM, Remington JS. In vitroactivity of the macrolide antibiotics azithromycin,roxithromycin and spiramycin againstToxoplasma gondii.Eur J ClinMicrobiol Infect Dis1991; 10: 519-524.
  4. Brun – Pascaud M, Rajagopalan-Levasseur P,Chau F, Bertrand G, Garry L, Derouin F, et al. Drugevaluation of concurrent Pneumocystis carinii,Toxoplasma gondii, and Micobacteriumaviumcomplex infections in a rat model. AntimicrobAgents Chemother 1998; 42: 1068-1072.
  5. Glacometti A, Cirioni O, Scatise G. In vitro activityof macrolide alone and in combination withartemisin, atovaquone, dapsone, minocycline orpyrimethamine against Cryptosporidium parvum.J AntimicrobChemother 1996; 38: 399-408.
  6. Hicks P, Zwipner RJ, Squres J, Savell V.Azithromycin therapy for Cryptosporidiumparvuminfection in four children infected withhuman immune deficiency virus. J Pediatr 1996; 129: 297-300.
  7. Taylor WR, Richie TL, Fryauff DJ, Picarima H, OhrtC, Tang D, et al. Malaria prophylaxis usingazithromycin: A double blind placebo controlledtrial in Irian Jaya, Indonesia. Clin Infect Dis 1999; 28: 74-81.
  8. Debrabant A, Joshi MB, Pimenta PF, Dwyer D.Generation of Leishmaniadonovaniaxenicamastigotes: their growth and biologicalcharacteristics. Int J Parasitol 2004; 34: 205-217.
  9. Sereno D, Lemesre JL. Axenically culturedamastigote forms as an in vitro model forinvestigation of antileishmanial agents.Antimicrob Agents Chemother 1997; 41: 972-976.
  10. Callahan H, Kelley C, Peretra T, Grogle M. Microtubule inhibitors: structure-activity analysissuggest rational models to identify potentiallyactive compounds. Antimicrob AgentsChemother 1996; 40: 947-952.
  11. Lemmure JI. Methods for the culture in vitro ofdifferent stages of tissue parasites.Internationalpublication 1994; WO 94/26899.
  12. Lemesre JL, Sereno D, Daulouede S, Veyret B,Brajon B, Vincendeau P. Leishmania spp.: nitricoxide mediated metabolite inhibition ofpromastigote and axenically grown amastigoteforms. ExpParasitol 1997; 86: 58-68.
  13. Sereno D, Lemesre JL. Use of enzymatic in vitromicromethod to quantify amastigote stage ofLeishmaniaamazonensis in vitro.Parasitol Res1997; 83: 401-403.
  14. Ouellette M, Papadopoulou B. Mechanism ofdrug resistance in Leishmania. Parastitol Today1993; 9: 150-153.
  15. Ullman B. Multidrug resistance and P-glycoproteinin parasitic protozoa. J BioenergBiomembr 1995;27:77-84.
  16. Ullman B, Carrero-Valenzuella E, Coons T.Leishmaniadonovani: isolation andcharacterization of sodium stibogluconate(Pentostam)-resistant cell lines. ExpParasitol 1989;69:157-63.
  17. Berman JD. Treatment of new world cutaneousand mucosal leishmaniases.ClinDermatol 1996;14: 519-522.
  18. Berman JD. Human leishmaniasis: clinicaldiagnostic and chemotherapeuticdevelopments in the last 10 years. Clin Infect Dis1997; 24: 684-703.
  19. Murray HW, Oca MJ, Granger MM, Schrieber RD.Requirement for T cells and effect of lymphokinesin successful chemotherapy for an intracellularinfection. Experimental visceral leishmaniasis. JClin Invest 1989; 83: 1253-1257.
  20. Chambers HF. Antimicrobial agents: proteinsynthesis inhibitors and miscellaneousantibacterial agents. In: Hardman JG, Limbird LE,Gilman AG, editors. Goodmans and Gilman’s ThePharmacological Basis of Therapeutics.McGraw-Hill; 2006. p. 1239-1271.
  21. Kroleweick A, Leon S, Scott P, Abraham D.Activity of azithromycin against Leishmania majorin vitro and in vivo. Am J Trop Med Hyg 2002; 67: 273-277.
  22. Stott GA. New macrolide antibiotics:clarithromycin and azithromycin. AmFamPhysician 1992; 46: 863-869.
  23. Giacometti A, Cirioni O, Scalise G. In vitro activityof macrolide alone and in combination withartemisin, atovaquone, dapsone, minocycline orpyrimethamine against Cryptosporidium parvum.J AntimicrobChemother 1996; 38: 399-408.
  24. de Oliveira-Silva F, de Morais-Teixeira E, RabelloA. Antileishmanial activity of azithromycin againstLeishmania(Leishmania) amazonensis,Leishmania(Viannia) braziliensis, and Leishmania(Leishmania) chagasi.. Am J Trop Med hyg 2008;78: 745-749.
  25. Tanyuksel M, Bas AL, Araz E, Aybay C.Determination of intracellular efficacies ofazithromycin against Leishmania major infectionin human neutrophils in vitro. Cell BiochemFunct2003; 21: 93-96.

Author Info

 

Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

iomcworld scan

Journal Highlights

Journal Flyer

Flyer